PNC Financial Services Group Inc. reduced its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,200 shares of the company’s stock after selling 408 shares during the period. PNC Financial Services Group Inc.’s holdings in Neurocrine Biosciences were worth $285,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. ARS Investment Partners LLC purchased a new stake in Neurocrine Biosciences in the second quarter valued at $207,000. Stephens Inc. AR purchased a new stake in Neurocrine Biosciences in the second quarter valued at $207,000. Grandfield & Dodd LLC lifted its position in Neurocrine Biosciences by 15.2% in the second quarter. Grandfield & Dodd LLC now owns 6,130 shares of the company’s stock valued at $282,000 after acquiring an additional 810 shares during the last quarter. Teacher Retirement System of Texas lifted its position in Neurocrine Biosciences by 0.8% in the second quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock valued at $320,000 after acquiring an additional 57 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its position in Neurocrine Biosciences by 11.9% in the second quarter. Pacer Advisors Inc. now owns 10,977 shares of the company’s stock valued at $505,000 after acquiring an additional 1,167 shares during the last quarter. 96.27% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/22/neurocrine-biosciences-inc-nbix-stake-lessened-by-pnc-financial-services-group-inc.html.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at 59.03 on Friday. The firm has a 50-day moving average of $59.44 and a 200-day moving average of $51.85. The firm’s market capitalization is $5.21 billion. Neurocrine Biosciences, Inc. has a 1-year low of $37.35 and a 1-year high of $63.77.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The firm had revenue of $6.34 million for the quarter, compared to the consensus estimate of $0.61 million. During the same quarter in the prior year, the firm posted ($0.46) EPS. On average, analysts expect that Neurocrine Biosciences, Inc. will post ($2.45) earnings per share for the current year.

A number of equities research analysts recently weighed in on NBIX shares. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, September 7th. ValuEngine raised shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Jefferies Group LLC reissued a “buy” rating and issued a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. BMO Capital Markets reissued an “outperform” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 5th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, September 21st. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $68.81.

In related news, insider Haig P. Bozigian sold 22,500 shares of Neurocrine Biosciences stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $50.00, for a total value of $1,125,000.00. Following the sale, the insider now directly owns 154,601 shares in the company, valued at approximately $7,730,050. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Christopher Flint Obrien sold 6,925 shares of Neurocrine Biosciences stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $61.04, for a total transaction of $422,702.00. Following the completion of the sale, the insider now owns 55,898 shares in the company, valued at $3,412,013.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 132,580 shares of company stock worth $7,440,850. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.